Since joining Myriad in December 2023, Sam has played an integral role in shaping the Company’s long-term growth strategy, while delivering new perspectives and expertise to advance our business initiatives,

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a collaboration with Gabbi, a telehealth solution for breast cancer risk assessment and specialist care services.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial intelligence (AI)-enabled prognostic and predictive tests for advancing access to personalized medicine and empowering treatment decisions,

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Monday reported a loss of $42.5 million in its fourth quarter. On a per-share basis, the Salt Lake City-based company ...

Myriad Genetics, Inc. engages in the discovery ... Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of ...

SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and PATHOMIQ, Inc., a developer of artificial